NCT00556712View on ClinicalTrials.gov

A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)

PHASE3CompletedINTERVENTIONAL
Enrollment

889

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

November 30, 2010

Study Completion Date

November 30, 2010

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

erlotinib [Tarceva]

150mg po daily

DRUG

Placebo

po daily

Trial Locations (133)

1000

Ljubljana

1009

Auckland

1062

Caracas

1122

Budapest

1125

Budapest

1140

Vienna

1145

Vienna

1529

Budapest

1900

Timișoara

2020

Antwerp

2045

Törökbálint

2065

St Leonards

2196

Johannesburg

2298

Waratah

2650

Edegem

2730

Herlev

3065

Fitzroy

3084

Melbourne

3220

Geelong

4091

Durban

4101

Brisbane

4400

Nyíregyháza

5000

Odense

5041

Adelaide

6020

Innsbruck

6600

Iași

6772

Deszk

7635

Pécs

9010

Klagenfurt

9700

Szombathely

11200

George Town

11527

Athens

14564

Athens

15006

A Coruña

16816

Neuruppin

21079

Dijon

29200

Brest

31400

Toulouse

33006

Oviedo

39008

Santander

40139

Bologna

44625

Herne

44791

Bochum

46026

Valencia

50009

Zaragoza

54511

Vandœuvre-lès-Nancy

59020

Lille

59100

Kuala Lumpur

61024

Kharkiv

63003

Clermont-Ferrand

64046

Pau

64100

Bayonne

69104

Zaporizhzhya

71110

Heraklion

72037

Le Mans

75674

Paris

75908

Paris

78052

Villingen-Schwenningen

87042

Limoges

88000

Uzhhorod

92288

Klaipėda

99437

Bad Berka

100730

Beijing

105203

Moscow

105229

Moscow

115478

Moscow

117837

Moscow

125284

Moscow

143900

Balashikha

150054

Yaroslavl

163045

Arkhangelsk

188663

Kuzmolovo

191015

Saint Petersburg

195067

Saint Petersburg

197022

Saint Petersburg

200032

Shanghai

350040

Krasnodar

354057

Sashi

400015

Cluj-Napoca

420029

Kazan'

420111

Kazan'

510060

Guangzhou

510080

Guangzhou

603000

Nizhny Novgorod

VIC 3165

East Bentleigh

R3E 0V9

Winnipeg

L1G 2B9

Oshawa

P6A 2C4

Sault Ste. Marie

M4C 3E7

Toronto

H7M 3L9

Laval

H4J 1C5

Montreal

0000

Santiago

370 87

České Budějovice

775 20

Olomouc

305 99

Pilsen

06120

Halle

00168

Rome

Unknown

Ancona

Kaunas

Christchurch

Kirov

Krasnodar

Saint Petersburg

Smolensk

Golnik

Maribor

Suwon

08660

Vilnius

1081 HV

Amsterdam

4382 EE

Flushing

6419 PC

Heerlen

3435 CM

Nieuwegein

91-520

Lodz

94-306

Lodz

05-400

Otwock

022328

Bucharest

454 087

Chelyabinsk

614 066

Perm

975 17

Banská Bystrica

825 56

Bratislava

949 88

Nitra

058 87

Poprad

0001

Pretoria

700-712

Daegu

110-744

Seoul

120-752

Seoul

135-710

Seoul

138-736

Seoul

139-709

Seoul

CM1 7ET

Chelmsford

DD1 9SY

Dundee

LE1 5WW

Leicester

PL6 8DH

Plymouth

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT00556712 - A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC) | Biotech Hunter | Biotech Hunter